Hetero launches biosimilar Adalimumab

Hyderabad: Hetero Labs Ltd, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, on Wednesday announced the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘MaburaTM’ in India. Hetero Healthcare will market and distribute the product in the country, according to a release.

Hetero further added in the release that “the product will be manufactured at our dedicated state-of-the-art manufacturing facility for Biologics, based at Hyderabad. MaburaTM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously. Hetero’s MaburaTM is the Biosimilar version of AbbVie’s HumiraTM. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.”

MaburaTM is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.